ROBOSENSE
22.12.2021 17:02:05 CET | Business Wire | Press release
RoboSense LiDAR , the leading smart LiDAR sensor provider, announced it will be exhibiting its latest cutting-edge LiDAR solutions at the Consumer Electronics Show (CES) on January 5 - 8 , 2022, starring RS-LiDAR M1 (M1), the world's first mass-produced automotive grade MEMS solid-state LiDAR. M1 will be joined at the stand by RS-Helios, the newest-generation bespoke LiDAR. RoboSense invites CES 2022 attendees to the West Hall, Tech East , Booth #6861, in Las Vegas, USA .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005289/en/
RoboSense is currently the only company in the world to have achieved mass-produced delivery of front-loading smart solid-state LiDAR. Looking ahead, RoboSense is sustainably empowered for the advent of the mass-produced LiDAR era with M1. Throughout 2021, RoboSense earned a large number of pre-installed fixed-point project orders from auto companies around the world, including the GAC Aion, WM Motor, ZEEKR (a Geely holding company), Lotus Cars, and Inceptio Technology.
M1’s extra small size makes it exceptionally convenient for front loading in mass production models. It is equipped with a unique smart "GAZE" function, which can dynamically and intelligently switch between far-field and near-field perception, substantially leveling up the performance of smart driving systems in different scenes.
This year, M1 has also been recognized for its innovation excellence and contribution to advancing smart mobility, winning a prestigious 2021 Automotive News PACE Award and a 2021 CLEPA Award from the European Association of Automotive Suppliers.
RoboSense is garnering worldwide recognition for its complete innovative portfolio in LiDAR and AI perception solutions. This is proven by its representing 10% of the global automotive pre-installed market, which ranks 1st in China and 2nd worldwide .
Taking the global stage at CES 2022, RoboSense will exhibit the latest LiDAR products and proven LiDAR technologies, including but not limited:
- RS-LiDAR-M1 , SOP version automotive-grade solid-state LiDAR
- RS-HELIOS-5515 , super-wide vertical FoV LiDAR
- RS-Bpearl , industrial unique design blind spot LiDAR
- RS-Ruby , upgraded 128-beam mechanical LiDAR
- RS-Ruby Lite , upgraded 80-beam mechanical LiDAR
- RS-Reference , full-stalk ground truth reference system
With RoboSense’s CES 2022 exhibition around the corner, all attendees - including clients, journalists, analysts, and industry partners - are welcome to visit RoboSense’s booth for detailed solution introductions and live product demonstrations. To schedule a meeting with RoboSense LiDAR and get exclusive access to news, or collaborate on upcoming stories and trends, please reach out to grace.ye@robosense.cn directly. An exciting world of smart mobility awaits.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. Comprising LiDAR sensors, AI algorithms and IC chipsets, its portfolio transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. The company's mission is to innovate outstanding hardware and artificial intelligence capabilities to create smart solutions that enable robots, including vehicles, to have perception capabilities superior to humans.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005289/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom